Spero Therapeutics (NASDAQ: SPRO)
Spero Therapeutics Return vs. S&P
| 1 Year | 5 Year | 5 Year Annualized | Since IPO |
|---|
Spero Therapeutics Company Info
Spero Therapeutics, Inc. is a clinical-stage biopharmaceutical company, which focuses on identifying, developing, and commercializing treatments involving bacterial infections, including multi-drug resistant bacterial infections, and rare diseases Its pipeline product candidates include Tebipenem HBr, SPR720, and SPR206. The company was founded by Ankit A. Mahadevia and Laurence Rahme in April 2013 and is headquartered in Cambridge, MA.
News & Analysis
Why Spero Therapeutics Stock Is Up 15% Today
The small biopharma's work has captured the attention of a much bigger player.
Why Spero Therapeutics Shares Are Sliding Today
The pricing of a stock offering is causing the drugmaker's shares to fall.
Valuation
Earnings Transcripts
Spero Therapeutics, Inc. (SPRO) Q3 2020 Earnings Call Transcript
SPRO earnings call for the period ending September 30, 2020.
Spero Therapeutics, Inc. (SPRO) Q2 2020 Earnings Call Transcript
SPRO earnings call for the period ending June 30, 2020.
Spero Therapeutics, Inc. (SPRO) Q1 2020 Earnings Call Transcript
SPRO earnings call for the period ending March 31, 2020.
Related Stocks
Premium Investing Services
Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.